Bristol-Myers Squibb Co
NYSE:BMY
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
39.46
59.82
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BMY stock under the Base Case scenario is 71 USD. Compared to the current market price of 58.87 USD, Bristol-Myers Squibb Co is Undervalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bristol-Myers Squibb Co
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BMY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Bristol-Myers Squibb Co
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health a...
Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world.
For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.
Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's core business segments primarily include:
-
Oncology: This is one of BMS’s most significant segments, encompassing a range of medications aimed at treating various types of cancer. Key products in this area include immune-oncology drugs, such as Opdivo (nivolumab) and Yervoy (ipilimumab), which are used for multiple cancer indications.
-
Immunology: BMS has a robust portfolio in immunology, focusing on treatments for autoimmune diseases. Key products in this segment include Orencia (abatacept) for rheumatoid arthritis and other autoimmune conditions, as well as other investigational therapies.
-
Cardiovascular: This segment includes medications that target cardiovascular conditions. BMS is known for its anticoagulant medications, such as Eliquis (apixaban), which is used in the prevention and treatment of blood clots.
-
Hematology: The hematology segment features treatments for blood cancers and disorders. Notable products include Revlimid (lenalidomide) and other therapies designed for the treatment of multiple myeloma and other hematologic malignancies.
-
Virology: This segment focuses on therapies for viral infections, most prominently HIV. BMS has developed various antiviral agents that play an essential role in the treatment and management of HIV.
-
Neuroscience and Other areas: While less emphasized compared to the segments above, BMS also invests in treatment options for various neurological disorders and other therapeutic areas, reflecting a commitment to expanding its product offerings.
Within these segments, BMS emphasizes research and development (R&D) to continuously innovate and bring new therapies to market, maintaining a strong pipeline of products aimed at tackling some of the most challenging global health issues.
This strategic segmentation allows BMS to leverage its capabilities across multiple therapeutic areas, driving growth and improving patient outcomes effectively.
Bristol-Myers Squibb Co (BMS) has several unique competitive advantages that set it apart from its rivals in the pharmaceutical industry:
-
Strong Pipeline of Innovative Drugs: BMS has a robust pipeline of products, particularly in oncology, immunology, and cardiovascular diseases. Its focus on research and development allows it to continually introduce new, high-demand therapies.
-
Diverse Portfolio of Blockbuster Drugs: The company has a diverse portfolio, including well-known products like Opdivo, Eliquis, and Yervoy. This diversity spreads risk and ensures multiple revenue streams.
-
Focus on Immuno-Oncology: BMS is a leader in immuno-oncology, a cutting-edge area of cancer treatment. Its pioneering efforts have placed it ahead of competitors in developing therapies that harness the immune system.
-
Strategic Acquisitions: BMS has made strategic acquisitions, such as the purchase of Celgene, which has enhanced its product offerings and access to innovative therapeutics, particularly in hematology.
-
Strong Financial Position: BMS has a solid financial foundation, with significant revenues and cash flow that allow for continued investment in R&D and marketing, sustaining its competitive edge.
-
Regulatory Expertise and Relationships: The company has substantial experience navigating the regulatory landscape, which can be a barrier for new entrants. Established relationships with regulatory bodies help expedite product approvals.
-
Global Reach: BMS operates in many international markets, allowing it to diversify its revenue and mitigate risks associated with dependence on a single market.
-
Commitment to Personalized Medicine: BMS is at the forefront of personalized medicine initiatives, focusing on biomarker-driven therapies that can lead to more effective treatments tailored to individual patients.
-
Sustainability and Corporate Responsibility: The commitment to sustainability and corporate responsibility enhances BMS’s brand reputation and can attract talent and investors who prioritize ethical considerations.
These competitive advantages enable Bristol-Myers Squibb to maintain a strong position in the pharmaceutical industry and effectively compete against other major players.
Bristol-Myers Squibb Co (BMS) faces several risks and challenges in the near future that could impact its performance and strategic initiatives:
-
Patent Expirations: The loss of patent protection for key drugs may lead to a decline in revenue as generic competitors enter the market. This is particularly relevant for high-revenue products.
-
Research and Development Risks: The pharmaceutical industry is inherently risky, with high failure rates in drug development. Delays or failures in clinical trials can affect the pipeline and future revenues.
-
Regulatory Challenges: BMS must navigate a complex regulatory environment. Changes in regulations or delays in approval processes can hinder the availability of new products.
-
Competitive Landscape: The biotechnology and pharmaceutical industries are highly competitive. New entrants or advancements from competitors can challenge BMS’s market position, particularly in oncology and immunology.
-
Pricing Pressure: Growing scrutiny over drug pricing from political entities and healthcare providers may lead to price reductions, impacting profitability.
-
Global Supply Chain Risks: Disruptions in the supply chain, whether due to geopolitical tensions, pandemics, or other factors, can impact production and distribution.
-
Market Volatility: Economic downturns or changes in healthcare funding can influence patient access to treatments, potentially affecting sales.
-
Strategic Integration: Following acquisitions, successful integration of new products, technologies, and cultures can present a challenge that impacts overall company performance.
-
Litigation Risks: The pharmaceutical industry can be subject to significant litigation risks, including patent disputes and liability claims, which can drain resources and management attention.
-
Emerging Health Threats: New diseases or health crises (like pandemics) can shift funding and attention away from BMS’s focus areas, potentially hampering strategic goals.
Strategically, BMS needs to manage these risks through careful planning, robust R&D processes, effective regulatory compliance, and proactive market positioning.
Revenue & Expenses Breakdown
Bristol-Myers Squibb Co
Balance Sheet Decomposition
Bristol-Myers Squibb Co
Current Assets | 28.1B |
Cash & Short-Term Investments | 8.1B |
Receivables | 14.9B |
Other Current Assets | 5.1B |
Non-Current Assets | 65.6B |
Long-Term Investments | 2.4B |
PP&E | 8.3B |
Intangibles | 48.7B |
Other Non-Current Assets | 6.2B |
Current Liabilities | 22.6B |
Accounts Payable | 3.5B |
Accrued Liabilities | 13.3B |
Short-Term Debt | 205m |
Other Current Liabilities | 5.7B |
Non-Current Liabilities | 53.9B |
Long-Term Debt | 48.7B |
Other Non-Current Liabilities | 5.2B |
Earnings Waterfall
Bristol-Myers Squibb Co
Revenue
|
47.4B
USD
|
Cost of Revenue
|
-11.4B
USD
|
Gross Profit
|
36B
USD
|
Operating Expenses
|
-24.9B
USD
|
Operating Income
|
11.1B
USD
|
Other Expenses
|
-18.4B
USD
|
Net Income
|
-7.3B
USD
|
Free Cash Flow Analysis
Bristol-Myers Squibb Co
USD | |
Free Cash Flow | USD |
In Q3 2024, Bristol-Myers Squibb reported a 20% increase in growth portfolio revenues, now making up half of total sales. Key achievements included FDA approval for Cobinfi, a new treatment for schizophrenia, adding significant growth potential. For 2024, the company raised its revenue guidance to around a 5% increase, driven by higher-than-expected sales of Revlimid, expected at $5.5 billion. The overall operating margin target remains at 37%, supported by a $1.5 billion cost savings initiative. With robust cash flow, BMS aims to pay down $10 billion in debt by mid-2026 while continuing to invest in its pipeline and maintaining dividends.
What is Earnings Call?
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Bristol-Myers Squibb Co's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Bristol-Myers Squibb Co's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for BMY is 58.46 USD with a low forecast of 33.43 USD and a high forecast of 76.65 USD.
Dividends
Current shareholder yield for BMY is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BMY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Contact
IPO
Employees
Officers
The intrinsic value of one BMY stock under the Base Case scenario is 71 USD.
Compared to the current market price of 58.87 USD, Bristol-Myers Squibb Co is Undervalued by 17%.